North America Radiofrequency Ablation Devices Market Segments and Growth by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

North America Radiofrequency Ablation Devices Market Forecast to 2027 - Covid-19 Impact and Regional Analysis by Product (Devices and Disposables) Application (Surgical Oncology, Cardiology, Gynecology, Cosmetology, and Pain Management), and Geography

  • Report Date : May 2020
  • Report Code : TIPRE00010856
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 120
Page Updated: May 2020

The North America radiofrequency ablation devices market is anticipated to reach US$ 3,214.24 Mn by 2027 from US$ 1,347.06 Mn in 2019. The market is projected to grow at a CAGR of 11.8% from 2020 to 2027.

The radiofrequency ablation devices transmit the energy of radiofrequency waves and destroy the target tissue. This technology has been widely in use to treat solid tumors, arrhythmias, uterine fibroids, and other medical conditions. The growth of the market in North America is driven by factors such as the increasing incidence of chronic illness and growing preference for minimally invasive proceduresin the region. However, side-effects associated with radiofrequency ablation restrain the market growth to a certain extent.

Growing healthcare expenditure is another factor contributing to growth of the North America radiofrequency ablation device market. The rise in the number of patients getting admitted to hospitals to cure suffering from different types of pain, highinsurance premium policies,and high deductibles in hospitals are among the factors responsible for the surge in healthcare costs. According to a study by the American Medical Association, in 2017,the US spent ~US$3.5 trillion on healthcare.Moreover, as per a study published in the Journal of the American Medical Association (JAMA) in March 2019, healthcare expenditure in the US during 1996–2015 rose nearly by US$ 1 trillion. The study reported that the overall healthcare spending in the US was US$3.5 trillion, i.e., ~US$11,000 per person,in 2017, and these costs are expected to climb to US$6 trillion—i.e., ~US$17,000 per person.Further, the increase in the incidence of chronic conditions has had a direct impact on increases in the cost of medical care, and almost half of the Americans have some form of chronic illness.

The RFA treatment is a prime trend in pain management nowadays, and in treatment of chronic illness associated with advancement in technology and healthcare infrastructure facilities is anticipated to havea positive influence in the revenue generation from radiofrequency ablation devices. Minimally invasive treatment procedures are associated with smaller incisions, less pain, shorter hospital stay, faster recovery, less scarring, and increased accuracy, which is leading to a greater preference for these procedures around the world. Moreover, due to lowered pain and discomfort, patients undergoing minimally invasive surgeries do not require large doses of painkillers. Such procedures have small size of the incision, which helps in healing faster than conventional surgeries, thereby allowing patients to get back to their normal lives as quickly as possible.Ablation is one of the most frequently used minimallyinvasive techniques for the treatment of various tumors, AF, and uterine fibroids.According to the American Society for Aestethic Plastic Surgery,the number of minimally invasive cosmetic procedures in the US increased from ~13.9 million in 2014 to 14.2 million in 2015.

The radiofrequency ablation procedure involves the injection of local anesthesia, followed by the insertion of a thin needle through a tiny incision to pass heat and electrical energy. The technology avoids scars and other risks associated with traditional open surgeries. Moreover, as the procedure is devoid of large cuts, it can be carried on extremely sick or old patients, as they cannot bear the stress associated with open surgeries. The completion of the total procedure takes 30–90 minutes, and the patients are monitored for a day, or in several cases, they are discharged on the same day. Further, they can recover in less time and can get back to daily life in ~1–3 weeks. Thus, the benefits associated with the minimal invasiveness of theprocedure of radiofrequency ablation treatment are driving the growth of the market.

North America is witnessing the rapidly growing number of COVID-19 cases; for instance, in the US, the number of cases has been increased to 614,246, with 26,064 deaths reported. According to the Breastcancer.org, in the country, many doctors, hospitals, and other healthcare facilities are delaying or canceling the breast cancer procedures and surgeries, as well as screenings or other treatments if they are not considered urgent, emergencies, or otherwise indicated for life-threatening conditions. Thus, the prevailing COVID-19 pandemic is likely to affect the radiofrequency ablation devices market growing in the coming months.

Mexico Radiofrequency Ablation Devices Market Revenue and Forecast to 2027 (US$Mn)

Mexico Radiofrequency Ablation Devices Market
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

NORTH AMERICARADIOFREQUENCY ABLATION DEVICES MARKET– MARKET SEGMENTATION


By Product

  • Devices
  • Disposables


By Applications

  • Surgical Oncology
  • Cardiology
  • Cosmetology
  • Gynecology
  • Pain Management


By Country

  • US
  • Canada
  • Mexico


Companies Profiled

  • Avanos Medical, Inc.
  • Stryker
  • Abbott
  • Boston Scientific
  • Bard (BD)
  • Angiodynamic
  • Hologic
  • Articure
  • Merit medical

North America Radiofrequency Ablation Devices Report Scope

Report Attribute Details
Market size in 2019 US$ 1,347.06 Million
Market Size by 2027 US$ 3,214.24 Million
Global CAGR (2020 - 2027) 11.8%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Product
  • Devices and Disposables
By Application
  • Surgical Oncology
  • Cardiology
  • Gynecology
  • Cosmetology
  • Pain Management
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Market leaders and key company profiles
  • Avanos Medical, Inc.
  • Stryker
  • Abbott
  • Boston Scientific
  • Bard (BD)
  • Angiodynamic
  • Hologic
  • Articure
  • Merit medical
  • Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Our Clients
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo